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Abstracts / Biol Blood Marrow Transplant 20 (2014) S72eS90 S85Patients were considered to have viral reactivation if CMV,
EBV and ADV copies/ml were 600, 1000 and 1000,
respectively. Viremia was deﬁned as peri-AlloHCT (d0 -
d+14), early viremia (d15 - d+98) and late viremia (d+99 -
d+180). From 2008- 2012, 100 consecutive children (median
age, 8 yrs; range 0.25-22 yrs; 35F/ 65M) undergoing
AlloHSCT for malignant (n¼53) and nonmalignant (n¼47)
disorders, were monitored. Donor sources included:
matched family donor (n¼ 42, 42%), matched unrelated do-
nors (n¼28, 28%) and unrelated cord bloods (n¼20, 20%).
Patients were conditioned with either myeloablative [MA]
(n¼43, 43%), reduced toxicity [RT] (n¼35, 35%), or reduced
intensity [RI] (n¼22, 22%) regimens. Additionally, a total of
79 patients (79%) received serotherapy with alemtuzumab
(n¼48, 48%) or rabbit-Anti-thymocyte globulin [r-ATG]
(n¼31, 31%).
The incidence of pre-AlloHCT viremia was 8%. The incidence
of post-AlloHCT single viremia, multiple viremia and viral
disease was 41, 15 and 22% respectively. The incidence of
peri-AlloHCT, early and late viremia was CMV: 5%, 22.2% and
6.6%; EBV: 1%, 9.1% and 1.1%; ADV: 5%, 10.1%, and 6.6%,
respectively. Viremia was noted in 36/80 (45%) of patients
who received serotherapy vs. 5/20 (25%) who did not receive
serotherapy (Chi-square test p¼0.1). Days for neutrophil,
platelet engraftment, incidence of graft failure and aGVHD
were not statistically signiﬁcant between patients with and
without viremia.
We performed univariate and multivariate analysis for risk
factors associated with viremia: age, sex, donor, stem cell
source, graft failure, CMV risk status, alemtuzumab, r-ATG,
malignant vs. non-malignant disease, MA vs. RT vs. RI regi-
mens, absolute neutrophil and lymphocyte count at day +30.
Only CMV risk status (p¼.0002) and pre-AlloHCT viremia (p¼
0.0095) were signiﬁcant on multivariate analysis. Among
patients with viremia vs. those without viremia, 1yr trans-
plant related mortality (TRM) and all-cause mortality was
23.7% vs. 16.7 (p¼.4) and 36.8% vs. 18.5% (p¼0.04),
respectively.
Among patients with viremia vs. without viremia, the me-
dian length of initial hospitalization (LOH) vs. LOH in the ﬁrst
180 days were 44 days (9-144) vs. 35(19-180) (p¼0.02) and
91 days ( 9-165) vs. 59 days (19-180), (p¼0.05) respectively.
Post-AlloHSCT viremia remains a signiﬁcant problem and
results in a signiﬁcantly longer LOH. Potentially due to
weekly monitoring the TRM was not signiﬁcantly higher in
patients with viremia.94
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The outcome of newly diagnosed children, adolescents and
young adults (CAYA) with lymphoma has improved signiﬁ-
cantly over the past 30 years. However, for patients with
poor-risk recurrent/refractory lymphoma, outcomes are still
dismal (<30%) despite intensive salvage therapy with mye-
loablative conditioning and autologous stem cell trans-
plantation (MAC AutoSCT) [Bradley/ Cairo, et al. BMT, 2008].
To address this problem, we designed a stem cell trans-
plantation approach to maximize an allogeneic graft versus
lymphoma effect in the setting of low disease burden (Cairo
et al. BBMT, 2013). We conducted a multi-center prospective
study of MAC-AutoSCT, followed by a reduced intensity
conditioning and allogeneic hematopoietic stem cell trans-
plant (RIC-AlloHSCT) in selected poor-risk CAYA, with re-
fractory or recurrent HL and NHL. Eligible patients with HD
had primary induction failure, early relapse (<12 months off
therapy, excluding patients with no prior therapy or radia-
tion only), or late relapse (>12 months off therapy, limited to
patients with stage III/IV disease and/or B symptoms at
relapse). Eligible patients with NHL had primary induction
failure or were in ﬁrst, second, or third relapse. Conditioning
for MAC-AutoSCT consisted of carmustine/etoposide/cyclo-
phosphamide (Harris/Cairo et al. BBMT, 2011). The RIC
regimen prior to AlloHSCT consisted of busulfan/ﬂudarabine
(Satwani/Cairo et al. BBMT, 2013). Thirty patients (16 HL and
14 NHL), median age of 16yrs and median follow-up of 5yrs,
were entered on study. Twenty three patients completed
both MAC-AutoSCT and RIC-AlloHSCT. Allogeneic sources
included unrelated cord blood (n¼9), unrelated donor (n¼8)
and matched sibling donor (n¼6). Following RIC-AlloHSCT
(n¼23), the incidence of grade II-IV aGvHD was 21.74% and
the probability of cGvHD was 13%. The incidence of trans-
plant related mortality following RIC-AlloHSCT was 12%. The
10 year event free survival (EFS) following sequential MAC-
AutoSCT and RIC-AlloHSCT (n¼23) was 64.0% (95% CI: 46.7%-
87.7%); EFS for patients with HL and NHL was 59.8% (95% CI:
37.8%-94.7%) and 70% (95%CI: 46.7%-100%) (p¼0.613),
respectively. Comparing primary refractory and relapsed
lymphoma patients undergoing tandem transplant, the 10
year EFS for patients with refractory disease vs. relapse
with stage III-IV disease vs. relapse with stage II disease was
71% vs. 60% vs. 66%, respectively. In summary, this novel
approach ofMAC-AutoSCT followed by RIC-AlloHSCT in CAYA
patients with poor risk lymphoma is feasible and safe. The
long-term EFS with this approach is encouraging considering
the poor-risk patient characteristics and the use of unrelated
donors for RIC-AlloHSCT in the majority of cases.95
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Monitoring of minimal residual disease (MRD) allo-SCT by
quantitative real-time PCR (qRT-PCR) of rearranged Ig- and
TCR-genes may highlight patients with highest risk for
relapse.
In the prospective phase 3 trial ALL-SCT-BFM-2003
(recruitment period 09/2003 to 09/2011; time point of
analysis May 2013), MRD was assessed in bone marrow
immediately on days +30, +60, +100, +200 and +365 post
transplantation in 115 patients. Of these, 48 were male and
67 were female patients. All received a myeloablative con-
ditioning regimenwith TBI and VP 16. Patients received their
transplant in CR2 (n¼94), CR3 (n¼21), CR4 (n¼1) or NR
(n¼2). The transplantations were performed with bone
marrow frommatched sibling donors (MSD, n¼23), matched
unrelated donors (MUD, n¼71) or with T-cell depleted stem
cells from mismatched donors (MMD, n¼21). Fifty-four pa-
tients were younger than 10 and 61 patients were older than
10 years at the time of transplant.
Standardized quantiﬁcation of MRD was performed accord-
ing to the guidelines of the Euro-MRD-Group and MRD re-
sults were not released to the clinicians.
The total group of patients showed a pEFS of 0.520.10;
cumulative incidence of relapse (CIR) and cumulative
incidence of treatment related mortality (CI TRM) was
0.410.11 and 0.190.09, respectively. In 76 patients, MRD
could also be assessed prior to transplant: patients who
were MRD negative (n¼41) had a three year pEFS of
0.620.04, patients with a MRD load of <10E-3 (n¼28) of
0.490.14 and none of the patients who were MRD posi-
tive >1E-3 survived their disease. MRD values post
transplant were analyzed as time-dependent covariates.
When analyzed either for the different time points or for
the highest MRD value post transplant, MRD results had
always signiﬁcant inﬂuence on survival. Taken the highest
MRD value post transplant, probabilities of pEFS and CIR
were 0.650.11 and 0.230.09 for MRD negative patients
(n¼72), 0.360.18 resp. 0.75 0.18 for patients with MRD
<10-3 (n¼36) compared to 0.000.0 and 1.00.0 in pa-
tients who developed MRD 10-3leukemic cells (n¼07)
(pEFS, P<0.0001; CIR, P<0.0001). In multivariate cox
regression analysis, MRD prior and post transplantation,
as well as indication for SCT, signiﬁcantly inﬂuenced the
probability of survival. It is noteworthy, that all patients
who developed a MRD load of >10E-3 at any time after
transplant ﬁnally developed relapse and died. However,
49% of patients who became MRD positive <10E-3 did not
necessarily develop frank relapse. Here, dynamic evolu-
tion needs to be considered as 9/15 patients with an MRD
load of <10E-3 at day 200 survived. However, if MRD was
not cleared by day 365 all patients ﬁnally relapsed.Assessment of MRD post transplant allows the identiﬁcation
of patients with impending relapse. All patients who devel-
oped MRD >10E-3 at any time post transplant ﬁnally
relapsed. Therefore, MRD may serve as an endpoint for
further pre-emptive therapies.96
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This study aims to describe outcomes of allogeneic cord
blood transplantation (CBT) in leukodystrophies (LD). LD are
rare inborn errors of metabolism in which the brain myelin
is primarily affected, characterized by rapid neurological
deterioration. Hematopoietic stem cell transplantation
(HSCT) can halt disease progression for selected leukodys-
trophies, including adrenoleukodystrophy (ALD), Krabbe
disease (globoid cell leukodystrophy) and metachromatic
leukodystrophy (MLD). Unrelated cord blood has the
advantage of being rapidly available.
All patients undergoing CBT for LD in EBMT centers between
1996 and 2012 were included. HSCT data were collected
from the EUROCORD database. An additional questionnaire
on disease-speciﬁc clinical outcomes was sent to
